Staphylococcus lugdunensis prosthetic joint infection: A multicentric cohort study - 29/11/22
on behalf of the
S. lugdunensis PJI study group#
Highlights |
• | S. lugdunensis PJI are difficult-to-treat, with a failure rate of 20%. |
• | An appropriate surgical strategy is crucial for treatment outcome. |
• | Rifampin-based regimens significantly improve outcome. |
• | DAIR should be restricted to patients with no other risk factor for treatment failure. |
• | Suppressive antimicrobial therapy is an acceptable alternative for high-risk patients. |
Abstract |
Objectives |
To describe Staphylococcus lugdunensis prosthetic joint infection (PJI) management and outcome.
Methods |
Adults with proven S. lugdunensis PJI were included in a multicentric retrospective cohort. Determinants for failure were assessed by logistic regression and treatment failure-free survival curve analysis (Kaplan-Meier).
Results |
One hundred and eleven patients were included (median age 72.4 [IQR, 62.7–79.4] years), with a knee (n = 71, 64.0%) or hip (n = 39, 35.1%) PJI considered as chronic in 77 (69.4%) cases. Surgical management consisted in debridement, antibiotic with implant retention (DAIR; n = 60, 54.1%), two-stage (n = 28, 25.2%) or one-stage (n = 15, 13.5%) exchange. Total duration of antimicrobial therapy was 13.1 (IQR, 11.8–16.9) weeks. After a median follow-up of 99.9 (IQR, 53.9–178.1) weeks, 22 (19.8%) S. lugdunensis-related treatment failures were observed. Independent determinants for outcome were diabetes (OR, 3.741; p = 0.036), sinus tract (OR, 3.846; p = 0.032), DAIR (OR, 3.749; p = 0.039) and rifampin-based regimen (OR, 0.319; p = 0.043). Twenty-four (40.0%) of the 60 DAIR-treated patients experienced treatment failure, with hip location (OR, 3.273; p = 0.048), delay from prosthesis implantation (OR, 1.012 per month; p = 0.019), pre-surgical CRP level >115 mg/L (OR, 4.800; p = 0.039) and mobile component exchange (OR, 0.302; p = 0.069) constituting additional determinants of outcome.
Conclusions |
Staphylococcus lugdunensis PJI are difficult-to-treat infections, with pivotal roles of an optimal surgical management.
Le texte complet de cet article est disponible en PDF.Keywords : Prosthetic joint infection, Rifampin, Staphylococcus lugdunensis
Plan
Vol 85 - N° 6
P. 652-659 - décembre 2022 Retour au numéro
Article précédent
- Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia
- Leyre Serrano, Luis Alberto Ruiz, Silvia Pérez, Pedro Pablo España, Ainhoa Gomez, Catia Cilloniz, Ane Uranga, Antoni Torres, Rafael Zalacain
- Effectiveness of influenza vaccination in reducing influenza-like illness and related antibiotic prescriptions in adults from a primary care-based case-control study
- Wen-Qiang He, Christopher Gianacas, David J Muscatello, Anthony T Newall, Peter McIntyre, Allen C Cheng, Bette Liu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?